Yinon Neriah-Ben
Jerusalem, JM, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML.
Journal: Journal of hematology & oncology
Published: May 06, 2025
Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML.
Journal: Research square
Published: November 01, 2024
Inhibition of nucleo-cytoplasmic proteasome translocation by the aromatic amino acids or silencing Sestrin3-their sensing mediator-is tumor suppressive.
Journal: Cell death and differentiation
Published: April 16, 2024
RORc-expressing immune cells negatively regulate tertiary lymphoid structure formation and support their pro-tumorigenic functions.
Journal: Journal of hepatology
Published: January 18, 2024
Putative homeostatic role of cancer driver mutations.
Journal: Trends in cell biology
Published: June 01, 2021
Immunity in acute myeloid leukemia: Where the immune response and targeted therapy meet.
Journal: European journal of immunology
Published: November 08, 2020
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic.
Journal: Nature
Published: April 02, 2019
β-TrCP upregulates HIF-1 in prostate cancer cells.
Journal: The Prostate
Published: September 13, 2018
CK1α ablation in keratinocytes induces p53-dependent, sunburn-protective skin hyperpigmentation.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 08, 2017
Last Updated: 09/26/2026